Intracellular activity of trovafloxacin (CP-99,219) against Enterococcus faecium

• Published in: Journal of antimicrobial chemotherapy Vol. 39; no. 4; pp. 552 - 553
• Main Authors: Herrera-Insúa, I, Jacques-Palaz, K, Murray, B E, Rakita, R M
• Format: Journal Article
• Language: English
• Published: England 01.04.1997
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Infective Agents - pharmacokinetics; Anti-Infective Agents - pharmacology; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Enterococcus faecium; Enterococcus faecium - drug effects; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines - pharmacokinetics; Naphthyridines - pharmacology; Neutrophils - drug effects; Neutrophils - microbiology; Vancomycin - pharmacology

Enterococcus faecium, a significant nosocomial pathogen, has developed resistance to multiple antibiotics, stimulating a search for new effective antimicrobials. The new quinolone trovafloxacin (CP-99,219) has good in-vitro activity against Gram-positive cocci, including E. faecium. We evaluated the...